Xilio Therapeutics Inc
NASDAQ:XLO
Intrinsic Value
The intrinsic value of one XLO stock under the Base Case scenario is 2.11 USD. Compared to the current market price of 0.78 USD, Xilio Therapeutics Inc is Undervalued by 63%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Xilio Therapeutics Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Xilio Therapeutics Inc
Balance Sheet Decomposition
Xilio Therapeutics Inc
Current Assets | 123.7m |
Cash & Short-Term Investments | 121.6m |
Other Current Assets | 2.2m |
Non-Current Assets | 10.1m |
PP&E | 8.3m |
Other Non-Current Assets | 1.8m |
Free Cash Flow Analysis
Xilio Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Xilio Therapeutics Inc
Revenue
|
15m
USD
|
Operating Expenses
|
-71.7m
USD
|
Operating Income
|
-56.6m
USD
|
Other Expenses
|
427k
USD
|
Net Income
|
-56.2m
USD
|
XLO Profitability Score
Profitability Due Diligence
Xilio Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Xilio Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
XLO Solvency Score
Solvency Due Diligence
Xilio Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Xilio Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XLO Price Targets Summary
Xilio Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for XLO is 2.04 USD with a low forecast of 2.02 USD and a high forecast of 2.1 USD.
Dividends
Current shareholder yield for XLO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one XLO stock under the Base Case scenario is 2.11 USD.
Compared to the current market price of 0.78 USD, Xilio Therapeutics Inc is Undervalued by 63%.